NICE Javlor ''torture'' could have international ripple effect
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has again decided that there is not enough conclusive evidence to recommend Pierre Fabre's Javlor (vinflunine) for treating bladder cancer after prior platinum treatment has failed. The decision is a disaster and other markets as far afield as Mexico could take up the decision too, said Martin Grange, Pierre Fabre's UK managing director. "The impact NICE has on the world is devastating," he said.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.